Poland· PL-100248323

Torecan

A thiethylperazine product containing thiethylperazinum, registered in Poland by Krka, d.d., Novo mesto. The same ATC class is registered in 3 of our 19 countries.

ATC R06AD03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedTorecanATCR06AD03REGISTER NO.PL-100248323PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Thiethylperazine is registered in 3 of 19 countries.

Countries holding a registration under ATC R06AD03 (thiethylperazine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose

Thiethylperazine · ATC R06AD03

3 / 19 countries

  • Czechiaprice
  • Finlandprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Thiethylperazinum
Manufacturer
Krka, d.d., Novo mesto
Country
Poland (PL)
ATC code
R06AD03
ATC class
Thiethylperazine
Defined daily dose
13 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909990242610

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

459 interactions on record for thiethylperazine.

Graded by severity as the source publishes them — 18 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Thiethylperazine · interactions on record

459 records

  • 18 severe
  • 430 moderate
  • 10 minor

Most severe, free to view

  • MetoclopramideA03FA01severe
  • Potassium chlorideA12BA01severe
  • Potassium citrateA12BA02severe
  • Potassium chlorideB05XA01severe

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Thiethylperazine in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All thiethylperazine products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Czechia · Torecan
  • Croatia · Torecan
  • Slovenia · Torecan
  • Slovakia · Torecan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3d76e3be-e7a5-49c1-b1c3-8d90306b5530
GET /v1/drugs/3d76e3be-e7a5-49c1-b1c3-8d90306b5530?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Czopki",
  "source": "urpl",
  "strength": "6,5 mg",
  "packaging": "05909990242610 ¦ Rp ¦ 10107\n6 szt.",
  "substance": "Thiethylperazini dimaleas 10.3 mg",
  "common_name": "Thiethylperazinum",
  "pl_product_id": "100248323",
  "pozwolenie_nr": "02426",
  "auth_procedure": "NAR",
  "authorisation_validity": "2026-01-13"
}

See everything about thiethylperazine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.